Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
600196
Peringkat dalam Saham
#2197
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical... Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
Harga Saham
$3.40
Kapitalisasi Pasar
$9.07B
Perubahan (1 hari)
-1.61%
Perubahan (1 tahun)
-16.08%
Negara
CN
Perdagangan Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Kategori
Healthcare
Rasio P/E untuk Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Shanghai Fosun Pharmaceutical (Group) Co., Ltd., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Shanghai Fosun Pharmaceutical (Group) Co., Ltd. dari 2001 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2025 | 20.86 | -12.71% |
| 2024 | 23.89 | -14.46% |
| 2023 | 27.93 | 13.42% |
| 2022 | 24.63 | -7.15% |
| 2021 | 26.52 | -29.79% |
| 2020 | 37.78 | 84.06% |
| 2019 | 20.52 | 2.24% |
| 2018 | 20.08 | -42.70% |
| 2017 | 35.03 | 83.27% |
| 2016 | 19.12 | -12.93% |
| 2015 | 21.95 | -4.19% |
| 2014 | 22.91 | -17.00% |
| 2013 | 27.61 | 111.33% |
| 2012 | 13.06 | -6.81% |
| 2011 | 14.02 | -52.13% |
| 2010 | 29.28 | 202.92% |
| 2009 | 9.67 | -48.95% |
| 2008 | 18.94 | -37.97% |
| 2007 | 30.53 | 48.06% |
| 2006 | 20.62 | -23.25% |
| 2005 | 26.87 | 31.61% |
| 2004 | 20.41 | 20.97% |
| 2003 | 16.88 | -39.62% |
| 2002 | 27.95 | -26.73% |
| 2001 | 38.15 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | - |
IN
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.